Celgene Targets Blood Cancers with Major Buys.
Sign Up to like & getrecommendations! Published in 2018 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-nb2018-007
Abstract: Celgene acquired Juno Therapeutics for $9 billion and is spending up to $7 billion on Impact Biomedicines in an effort to diversify its hematology portfolio with chimeric antigen receptor T-cell therapies and a JAK2 inhibitor… read more here.
Keywords: hematology; celgene targets; targets blood; major buys ... See more keywords
Cancers of the Major Salivary Gland.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of oncology practice"
DOI: 10.1200/jop.2017.026856
Abstract: Salivary gland malignancies are rare tumors that comprise multiple histologic entities with diverse clinical behavior. Mucoepidermoid carcinoma is the most frequent primary salivary malignancy, followed by adenoid cystic and acinic cell carcinoma. Although most salivary… read more here.
Keywords: cancers major; radiotherapy; major salivary; salivary gland ... See more keywords